首页|期刊导航|皮肤性病诊疗学杂志|青斑样血管病的抗炎治疗进展

青斑样血管病的抗炎治疗进展OA

Advances in anti-inflammatory therapy for Livedoid vasculopathy

中文摘要英文摘要

青斑样血管病是一种病因及发病机制尚未明确的血管病,目前尚无统一的诊疗指南.目前认为其发病机制与血液高凝状态有关,免疫、炎症也可能参与发病,抗炎治疗有效.青斑样血管病在抗炎方面的治疗药物主要包括植物生物碱(秋水仙碱、雷公藤多苷)、糖皮质激素、JAK抑制剂、阿达木单抗、静脉注射用免疫球蛋白及其他抗炎药物等.本文主要综述青斑样血管病的抗炎治疗和方法,以期为临床治疗提供参考.

Livedoid vasculopathy is a type of vascular disorder with unclear etiology and patho-genesis,in addition to the lack of standardized diagnostic and treatment guidelines.Currently,it is believed that the development of this disease is associated with blood hypercoagulability and in-flammation.However,studies also suggest the involvement of immune and inflammatory reactions in its pathogenesis.And anti-inflammatory therapy is effective.The drugs used for the treatment of livedoid vasculopathy include plant alkaloids(colchicine,tripterygium glycosides),glucocorti-coids,JAK inhibitors,adalimumab,intravenous immunoglobulins and anti-inflammatory drugs.This review aims to summarize the anti-inflammatory therapy and methods for livedoid vasculopa-thy,providing references for clinicians in the management of this disorder.

黄丹;温斯健

广西医科大学附属武鸣医院,广西 南宁 530199广西医科大学第一附属医院,广西 南宁 530021

青斑样血管病抗炎阿达木单抗JAK抑制剂

livedoid vasculopathyanti-inflammationadalimumabJAK inhibitor

《皮肤性病诊疗学杂志》 2024 (3)

209-213,5

广西自然科学基金(2020GXNSFAA297150)

10.3969/j.issn.1674-8468.2024.03.011

评论